Disabling overactivity of the extensor hallucis longus after stroke: clinical expression and efficacy of botulinum toxin type A

Arch Phys Med Rehabil. 2003 Jan;84(1):147-9. doi: 10.1053/apmr.2003.50077.

Abstract

Objectives: To describe the clinical characteristics of persistent extension of the great toe related to overactivity of the extensor hallucis longus (EHL) after a stroke and to explore the efficacy of treatment with botulinum toxin type A.

Design: Case series.

Setting: A physical medicine and rehabilitation department in France.

Participants: Eleven patients with hemiplegia disabled by overactivity of the EHL were classified according to the different ways in which that overactivity was triggered. Disability was related to pain in 5 patients, to shoe difficulties in 10 patients, and to varus foot in 6 patients.

Intervention: Injection of botulinum toxin type A into the EHL.

Main outcome measures: Efficacy was assessed on day 15 by triggering of pain, shoe difficulties, and varus deformity and by patients' subjective assessment on day 15, at 3 months, and at 6 months.

Results: On day 15, EHL overactivity disappeared after 16 of the 18 injections in 10 patients; subjective assessment was very good for pain and shoe difficulties and remained good or very good at 3 months for 8 patients who received 12 injections.

Conclusion: Botulinum toxin type A is effective in treating disability related to poststroke overactivity of the EHL.

MeSH terms

  • Adult
  • Aged
  • Botulinum Toxins, Type A / therapeutic use*
  • Dystonic Disorders / drug therapy*
  • Dystonic Disorders / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Agents / therapeutic use*
  • Stroke Rehabilitation*
  • Toes / physiopathology*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A